(Boursier.com) — Cellectis today announced the publication of an article in Molecular Therapy – Methods & Clinical Development, demonstrating the effectiveness of its TALEN genome editing platform to edit the mutated PIK3CD gene in APDS1 T cells.
The research work described in this article was carried out jointly by the Imagine Institute and Cellectis teams.
©2023 Boursier.com